• Company News
  • Group Information

Published in the top chemistry journal! Maikokang Biological Adjuvant Team Collaborates to Publish New Adjuvant System Applied to Tumor Vaccines

2025-10-20
Recently, the cooperative research paper "Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjustments of 3D-MPL and QS-21", developed by Chengdu Maikekang Biotechn...
Company News Group Information

Milestones | Phase III clinical enrollment of MAXVAX recombinant herpes zoster vaccine (CHO cells)

2024-07-13
On July 13th, the Phase III clinical trial of the recombinant herpes zoster vaccine (CHO cells) of Chengdu MAXVAX Biotechnology Co., Ltd. (referred to as "MAXVAX Biotechnology") completed with the ...
Group Information

Chengdu Daily | Mark, Chief Scientist of Chengdu Enterprises: Matchmaker to Accelerate Chengdu Enterprises' Going Global

2024-07-12
The key to international cooperation in technological innovation is to establish communication and connections, and the best way to achieve this is through people with good relationships international
Group Information

The first domestically developed recombinant respiratory syncytial virus vaccine (CHO cells) has been approved for clinical use!

2024-06-28
On June 28, 2024, Chengdu MAXVAX Biotechnology Co., Ltd. announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has approved its application for clinica...
Group Information

Financing Progress | MAXVAX Biotechnology has completed its Series C financing, with a total of over 600 million yuan raised in Series C funding

2024-06-12
In June 2024, Chengdu MAXVAX Biotechnology Co., Ltd. (hereinafter referred to as "MAXVAX Biotechnology") announced that it had received over 300 million yuan in Series C financing. This round of...
Group Information

Chongqing Modern Industry Research Institute conducts research on the Maikekang Biological Innovation Vaccine Production Transformation Platform

2024-05-19
On the morning of May 19th, representatives from Chongqing Modern Industry Research Institute conducted research on the Shanghai Innovation Vaccine Transfer Platform of Maikekang Biotechnology. Mr. Zo
Group Information

The kickoff meeting for the Phase II clinical trial of the Meikokang Biological Recombinant Herpes Zoster Vaccine was successfully held

2024-05-16
On May 6th, the kickoff meeting for the Phase II clinical trial of the recombinant herpes zoster vaccine (CHO cells) by Chengdu Maikekang Biotechnology Co., Ltd. (referred to as "Maikekang Biotechnolo
Group Information

Yuan Quan District Chief of Fengxian District, Shanghai, led a team to investigate the use of the Maike Kang Biotechnology Shanghai production conversion platform

2024-04-20
On the morning of April 20th, Yuan Quan, Deputy Secretary of the Fengxian District Committee and District Mayor of Shanghai, led a team to investigate the "Innovative Vaccine Transfer Platform" projec
Group Information Company News

The IND application for the Class I innovative drug RSV vaccine of Maikokang Biotechnology has been accepted by CDE

2024-04-12
On April 12, 2024, Chengdu Maxvax Biotechnology Co., Ltd. (referred to as "Maxvax Biotechnology") announced that its independently developed and jointly applied by its wholly-owned subsidiary fo
Group Information Company News

2023BRD China (Shanghai) Biomedical Innovation and Development Conference

2023-11-29
On December 29, 2023, the BRD Shanghai Biomedical Innovation and Development Conference arrived as scheduled, with a gathering of experts on site. The preparatory party for this conference, Pharmaceut
Company News Group Information
Phone
+86-21-68403318
QQ
1905311766
WeChet
WeChet
Scan Code
On-Line
Submit